First steps in the treatment of advanced Parkinson’s disease with foslevodopa/foscarbidopa continuous subcutaneous infusion

Aim : The aim of this study was to evaluate the efficacy and safety of this new therapy in Bulgaria. The second objective was to determine whether foslevodopa/foscarbidopa infusion improves the quality of life of patients. Materials and methods : This study observed 24 patients with advanced Parkinson’s disease. Neurological examination, MDS–UPDRS, Parkinson’s Disease Sleep Scale, Parkinson’s Disease Quality of Life Questionnaire, and the Bulgarian version of EQ–5D–5L were used. Results : All patients showed improvement in motor fluctuations, nocturnal akinesia, and quality of life. In almost 68% of patients, monotherapy was not possible, and a dopamine agonist had to be added. The main side effects were non-serious skin reactions. Conclusion : Foslevodopa/foscarbidopa is a new method for the treatment of advanced Parkinson’s disease. The therapy improves motor function and has a positive effect on nocturnal akinesia and quality of life. Overall, the drug demonstrates a good safety profile and tolerance.